Corsearch Announces Strategic Partnerships with Key-Systems GmbH and INCOPRO
Corsearch, a premier provider of clearance and protection solutions for trademark and brand professionals, is pleased to announce strategic partnerships with Key-Systems, a global player in the internet and domain industry, and INCOPRO, a leading online IP and brand protection company. The agreements solidify Corsearch’s full service domain management and brand protection offerings for law firms .
“We are thrilled to be moving forward in a new partnership with Key Systems to complement our existing partnership with COM LAUDE, and to be expanding the partnership we have with INCOPRO,” said Corsearch President and CEO Tobi Hartmann. “These relationships will allow Corsearch to expand its domain name management and brand protection solutions for law firms and their end clients.”
Corsearch & Key-Systems Partnership
Working with the corporate domain management solution “BrandShelter", Corsearch will provide law firms an easy way to manage the domain portfolios of their clients. This collaboration will provide law firms powerful and stable domain management through one of the largest registrars in Europe.
“We are excited to have won Corsearch as a partner,” said Alexander Siffrin, Key-Systems CEO. “Our customers will benefit from our joint expertise and excellence.”
In addition to the fully automated and white labeled interface, this cooperation allows Corsearch and Key-Systems to provide a dedicated account management team of industry experts, automatic renewal of all domains in management, and a completely automated and customizable billing system which is able to send invoices in the law firm’s name with the given pricing for their clients.
Corsearch & INCOPRO Partnership
Corsearch & INCOPRO today announce a renewal of their collaboration aimed at enabling law firms to deliver strategic advice and online enforcement for their clients. Corsearch will offer a law firm edition of INCOPRO’s innovative brand protection technology, providing law firms with the technology to defend their clients’ intellectual property from online abuse.
“As a lawyer myself, I know that technology has a huge role to play in enabling law firms to deliver strategic and cost-effective advice and support to clients,” said INCOPRO CEO Simon Baggs. “INCOPRO is thrilled to be working with Corsearch in delivering this new and exciting solution.”
Online IP infringement is a rapidly growing challenge for all brands as e-commerce expands and digital becomes the core business strategy. Using the Corsearch INCOPRO platform, law firms can efficiently identify the strategic challenges affecting their clients’ brands, adding to the value they offer their clients and strengthening their IP services.
Corsearch will be the exclusive provider of this law firm edition of the INCOPRO system, offering a market-leading proposition to its law firm clients. Corsearch & INCOPRO first partnered in 2016 and this new proposition reinforces the strength of the partnership.
Corsearch is a premier provider of clearance and protection solutions for trademark and brand professionals. Its high-quality, intuitive tools and unparalleled expertise enable professionals to effectively manage their trademark screening, search review, watching, and domain management processes. With highly trained researchers, an expansive global content set and customer-focused technology tools available through the Corsearch platform, Corsearch empowers its customers with powerful brand solutions in an increasingly complex business environment.
For more information visit Corsearch.com.
Founded in 1998, Key-Systems is a global player of the internet and domain industry. Its core business is the registration of internet addresses – Key-Systems currently manages more than 5 million domains on behalf of its customers.
Besides domain registrations, Key-Systems' three differently targeted business divisions and the two wholly owned subsidiaries offer comprehensive IT services. These include the operation of a registry, colocation, virtual servers, web hosting, SSL certificates and brand monitoring on the Internet.
Key-Systems serves customers all over the world, among them are private clients, mid-sized businesses, well-known domain investors as well as large international organizations and corporations. With diversified offerings, trusted technique, and our experienced team of more than 100 domain experts Key-Systems expanded its customer base to more than 100,000 retail/corporate customers and over 2,300 resellers worldwide. For more information regarding Key-Systems GmbH, visit www.key-systems.net.
Founded in 2011, INCOPRO is an online IP and brand protection company. Its proprietary technology platform TALISMAN collates data on brand infringement and automatically identifies and prioritizes IP violations. Its clustering technology is uniquely able to track and connect the commercial scale counterfeiters, enabling comprehensive takedown of all associated operations. Headquartered in London, with INCOPRO’s analysts working across the United States, Europe, and Asia, INCOPRO works with some of the largest global brands to provide connected and actionable insights into IP infringements online. For additional information regarding INCOPRO, please visit www.incoproip.com.
Brett Amdur, 800-732-7241
Chief Marketing and Strategy Officer
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an